September 16, 2025

CSL Commits $117M for Option to Acquire VarmX and Advance Novel Blood Clotting Therapy to Market

1 day ago talkbio0Tagged Acquisition, Anticoagulants, antithrombin III, blood clotting drug, critical bleeding, Partnership, SMPX gene, United States Food and Drug Administration, VarmX, VMX-C001

CSL; VarmX; VMX-C001; blood clotting drug; Factor Xa inhibitors; anticoagulants; Phase 3 clinical trial; acquisition; biotech partnership; critical bleeding; FDA fast-track

FDA Crackdown on Pharma TV Ads Targets Pfizer, Novartis, BMS, Lilly & Others

1 day ago talkbio0Tagged Burning Mouth Syndrome, Cautionary Warning, Correspondence as Topic, Crackdown, Direct-to-Consumer, drug marketing compliance, Eli Lilly, Novartis, Pfizer, pharma TV ads, provision, Sufficient, United States Food and Drug Administration

FDA crackdown; pharma TV ads; Pfizer; Novartis; BMS; Lilly; warning letters; direct-to-consumer advertising; adequate provision rule; drug marketing compliance

Areteia Therapeutics Posts Phase 3 Win for Oral Asthma Drug Dexpramipexole

1 day ago talkbio0Tagged Areteia, biologic blockbusters, Dexpramipexole, EXHALE-4, oral asthma therapy, Phase 3, Pulmonary Eosinophilia, topline

Areteia Therapeutics; dexpramipexole; Phase 3; oral asthma therapy; biologic blockbusters; eosinophilic asthma; EXHALE-4; topline results

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

1 day ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal

2 days ago talkbio0Tagged AI/ML-enabled product, Collaboration, Drug Discovery, engine, immune-mediated diseases, milestone payments, molecular glue degraders, Monte Rosa Therapeutics, MRT-6160, Novartis, VAV1 protein

Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine